CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Acute Hepatitis Panel

Defines medical necessity and coverage rules for the Acute Hepatitis Panel (HAV IgM, HBcAb IgM, HBsAg, HCV antibody) for BCBSRI Medicare Advantage and Commercial products, and specifies limitations on use and authorization practices affecting ordering providers and laboratories.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAcute Hepatitis Panel

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 5, 2026

Next Review DateMay 20, 2026

Key ActionOnly the ordering physician may be involved in authorization and appeal processes; laboratories may not obtain authorization on behalf of the ordering physician.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4tests included in the acute hepatitis panel

80074CPT panel code

Not applicablePrior authorization

Not applicableMedical criteria

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medically Necessary Indications

Covered when ALL of the following are met:

Indications for medical necessity: 1) Acute hepatitis panel testing is medically necessary to detect viral hepatitis infection when there are abnormal liver function test results, with or without signs or symptoms of hepatitis; 2) Testing is medically necessary prior to and subsequent to liver transplantation; and 3) The claim is filed with an appropriate covered diagnosis code.

Applies to Medicare Advantage Plans and Commercial Products

The acute hepatitis panel is not indicated as a screening test for Hepatitis B or Hepatitis C and is not indicated to assess prior vaccination against hepatitis A or hepatitis B. The panel is intended for diagnostic evaluation in the appropriate clinical context (for example, when there are abnormal liver function tests or in the pre- or post-liver transplant setting) rather than routine population screening or assessment of immunization status. Laboratories must follow ordering-provider directions for authorization; laboratories are not permitted to obtain authorization on behalf of the ordering physician.

Use of the acute hepatitis panel for indications other than detection of viral hepatitis in the setting of abnormal liver function tests or for evaluation prior to and after liver transplantation is not covered. For Medicare Advantage members these other indications are explicitly not covered; for Commercial members other indications are considered not medically necessary.

After a hepatitis diagnosis is established, ordering the entire panel is unnecessary; only individual tests specific to ongoing management should be performed. Laboratories are not permitted to obtain clinical authorization or act on behalf of the ordering physician in the authorization process, and unauthorized services provided by a laboratory may be denied and become the financial responsibility of the laboratory.

Commercial members may have additional contract exclusions (for example, certain genetic or specialized tests) that affect coverage; refer to the member's Benefit Booklet and related policy sections for plan-specific applicability.

Provider Actions and Billing Rules

Prior Authorization

Not applicable

Note

Limitations

- After a hepatitis diagnosis has been established, only individual tests, rather than the entire panel, are needed. - This panel is not indicated as a screening test for Hepatitis B or Hepatitis C, nor is it indicated as a test to assess for prior vaccination against hepatitis A or hepatitis B.

Documentation Required

Authorization ownership and documentation

Laboratories are not allowed to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician. Only the ordering physician shall be involved in the authorization, appeal or other administrative processes related to prior authorization/medical necessity. In no circumstance shall a laboratory or a physician/provider use a representative of a laboratory or anyone with a relationship to a laboratory and/or a third party to obtain authorization on behalf of the ordering physician, to facilitate any portion of the authorization process or any subsequent appeal of a claim where the authorization process was not followed and/or a denial for clinical appropriateness was issued, including any element of the preparation of necessary documentation of clinical appropriateness. If a laboratory or a third party is found to be supporting any portion of the authorization process, BCBSRI will deem the action a violation of this policy and severe action will be taken up to and including termination from the BCBSRI provider network.

Denial Risk

Unauthorized lab services billed by laboratory

If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

Unauthorized lab services billed by laboratory: will be denied and the participating laboratory is financially liable; charges may not be billed to the member.

Ordering Requirements

Step Therapy

Ordering requirements — ordering physician must handle authorizations/appeals

Only the ordering physician may be involved in authorization or appeal processes; laboratories may not obtain authorization on behalf of the ordering physician and must not use representatives or third parties to facilitate authorization or appeals.

Any laboratory involvement in authorization or appeals is a policy violation and may lead to severe action, including termination from the BCBSRI provider network.
Laboratories found to have supported authorization processes will have services denied and bear financial liability.

Not Covered

The acute hepatitis panel is not covered for the purpose of screening for Hepatitis B or Hepatitis C, or for assessing prior vaccination against hepatitis A or hepatitis B. Use of the panel for any indication other than abnormal liver function tests or pre/post liver transplant is not covered for Medicare Advantage and not medically necessary for Commercial products.

Once a diagnosis of hepatitis has been established, repeat or routine panel testing is not required; targeted individual tests should be used instead of the full panel. Laboratories and third parties are prohibited from obtaining authorizations on behalf of the ordering physician; if a laboratory provides services without proper authorization those services may be denied and charged to the laboratory. Commercial plan members may also be subject to contract-specific exclusions—consult the applicable Benefit Booklet and related policies.

Definitions and Test Marker Interpretations

Test marker interpretations — HAV, HBV, HCV

Hepatitis A (HAV) — IgMPositive IgM anti-HAV indicates acute HAV infection; IgM appears within ~4 weeks of exposure and disappears within ~3 months; IgG indicates prior exposure or immunization and persists indefinitely.

Hepatitis B — HBsAgHepatitis B surface antigen (HBsAg) is an early marker appearing ~4–8 weeks after exposure; persistence beyond 6 months indicates chronic HBV infection.

Hepatitis B — HBcAb IgMIgM antibody to hepatitis B core antigen (HBcAb‑IgM) is the best marker of acute HBV infection and is expected to appear ~2–3 months after exposure, declining over 1–2 years.

Hepatitis B — HBsAbHepatitis B surface antibody (HBsAb) appears ~4–6 months after exposure or following vaccination, persists indefinitely, and indicates immunity.

Hepatitis C (HCV) — AntibodyHCV antibody detects prior exposure and typically appears 2–4 months after infection; false positives can occur, so positive results are usually confirmed with a more specific test.

Frequency Limits

Acute Hepatitis Panel — repeat testing guidance

Indication for repeat testingIf the stage of disease or timing of exposure is uncertain and symptoms persist despite a completely negative initial panel, repeat the Acute Hepatitis Panel may be needed to exclude hepatitis.

Suggested timing for repeat panelRepeat testing is suggested approximately 2 weeks to 2 months after an initial negative panel when clinical suspicion remains.

When to use individual tests insteadOnce a specific hepatitis diagnosis is established, perform targeted individual tests (rather than the entire panel) to monitor disease course.

Background

Viral hepatitis is most commonly caused by Hepatitis A, B, or C. The Acute Hepatitis Panel (HAV IgM, HBcAb IgM, HBsAg, and HCV antibody) is used primarily to support the differential diagnosis of acute hepatitis and to detect viral hepatitis infection in patients with abnormal liver function tests or compatible clinical symptoms.

The timing of antigen and antibody appearance affects interpretation: for example, HBcAb IgM is the best marker for acute HBV infection, while HBsAg indicates early or active HBV infection, and HAV IgM indicates acute HAV infection. Because serologic markers evolve over time, repeat testing of the panel may be necessary if initial tests are negative but clinical suspicion remains.